You are here: Industry Insights > Sanofi

News List

Kymera Therapeutics, Sanofi collaborate to advance novel protein degrader therapies to patients pharmaceutical-business-review
July 15, 2020
Kymera Therapeutics announced the company has entered into a multi-program strategic collaboration with Sanofi to develop and commercialise first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.
Sanofi and Regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients worldpharmanews
July 14, 2020
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to ...
UK report finds low awareness of non-melanoma skin cancer pharmatimes
July 14, 2020
Public awareness in the UK about non-melanoma skin cancer (NMSC) is 'worryingly low' and 'urgent action' is needed to improve sun protection for outdoor workers, concludes a new report by Sanofi.
Sanofi partners with Kymera in $2bn protein degrader therapies deal pharmaceutical-technology
July 10, 2020
Sanofi has formed a multi-programme collaboration with biotechnology firm Kymera Therapeutics to develop and commercialise protein degrader therapies that target IRAK4 in immune-inflammatory diseases.
Kymera, Sanofi Enter Multi-program Strategic Alliance contractpharma
July 10, 2020
To develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases.
Britain nears $625 million Sanofi/GSK COVID-19 vaccine deal: report expresspharma
July 07, 2020
Clinical trials are due to start in September and Sanofi has said it expects to get approval by the first half of next year, sooner than previously anticipated.
Regeneron, Sanofi arthritis drug fails COVID-19 study expresspharma
July 06, 2020
Previous trial results had shown that the drug did not help patients with less severe COVID-19, the disease caused by the novel coronavirus.
Sanofi, Regeneron's pull plug on Kevzara COVID-19 trial pharmatimes
July 03, 2020
Sanofi and Regeneron have reported that a late-stage trial assessing the potential of arthritis drug Kevzara (sarilumab) has been stopped after it failed to hit targets.
Sanofi and Translate Bio Expand Vaccine Collaboration contractpharma
June 28, 2020
To develop mRNA vaccines across all infectious disease areas in a deal potentially worth up to $1.9 billion.
Sanofi and Translate Bio team up to develop mRNA vaccines pharmaceutical-technology
June 24, 2020
Sanofi vaccines business unit Sanofi Pasteur has expanded its existing 2018 partnership with messenger RNA (mRNA) therapeutics firm Translate Bio for the development of mRNA vaccines against various infectious diseases.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page